Acer Therapeutics Inc.

OTCPK:ACER Stock Report

Market Cap: US$19.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Acer Therapeutics Management

Management criteria checks 3/4

Acer Therapeutics' CEO is Chris Schelling, appointed in Dec 2013, has a tenure of 9.92 years. total yearly compensation is $834.28K, comprised of 59.9% salary and 40.1% bonuses, including company stock and options. directly owns 11.09% of the company’s shares, worth $2.18M. The average tenure of the management team and the board of directors is 4.2 years and 6.2 years respectively.

Key information

Chris Schelling

Chief executive officer

US$834.3k

Total compensation

CEO salary percentage59.9%
CEO tenure9.9yrs
CEO ownership11.1%
Management average tenure4.2yrs
Board average tenure6.2yrs

Recent management updates

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25
Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Recent updates

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Oct 05

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Aug 12

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Jul 28

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Jul 18

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

Feb 11
Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Aug 31

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

May 20
We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25
Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Dec 22

CEO Compensation Analysis

How has Chris Schelling's remuneration changed compared to Acer Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$834kUS$500k

-US$26m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$552kUS$436k

-US$15m

Sep 30 2021n/an/a

-US$17m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$676kUS$436k

-US$23m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$1mUS$436k

-US$29m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$31m

Mar 31 2019n/an/a

-US$25m

Dec 31 2018US$550kUS$400k

-US$21m

Sep 30 2018n/an/a

-US$17m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$585kUS$117k

-US$14m

Sep 30 2017n/an/a

-US$12m

Jun 30 2017n/an/a

-US$11m

Mar 31 2017n/an/a

-US$9m

Dec 31 2016US$469kUS$469k

-US$7m

Compensation vs Market: Chris's total compensation ($USD834.28K) is about average for companies of similar size in the US market ($USD740.57K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Schelling (47 yo)

9.9yrs

Tenure

US$834,280

Compensation

Mr. Christopher Schelling, also known as Chris, Founded Acer Therapeutics Inc. in December 2013 and has been its President and Chief Executive Officer since September 2017 and served as its Chief Operating...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Schelling
Founder9.9yrsUS$834.28k11.09%
$ 2.2m
Harry Palmin
Chief Financial Officer7.8yrsUS$592.59k0.51%
$ 100.6k
Adrian Quartel
Chief Medical Officer1.8yrsUS$857.63k0%
$ 0
Tanya Hayden
Chief Operating Officer1.4yrsno datano data
John Klopp
Chief Technical Officer4.2yrsno datano data
Donald Joseph
Chief Legal Officer & Secretary5.6yrsUS$490.28kno data
Bernie Paul
Chief People Officer3.1yrsno datano data
Jefferson Davis
Chief Business Officer2.8yrsUS$634.80k0.29%
$ 57.6k
Jason Kneeland
VP of Finance & Controller6yrsno datano data

4.2yrs

Average Tenure

54.5yo

Average Age

Experienced Management: ACER's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Schelling
Founder6.2yrsUS$834.28k11.09%
$ 2.2m
Stephen Aselage
Independent Chairman of the Board6.2yrsUS$104.95k1.98%
$ 389.2k
Michelle Griffin
Independent Director6.2yrsUS$88.08k0%
$ 0
Stuart J. Swiedler
Member of the Scientific Advisory Boardno datano datano data
John Dunn
Independent Director6.2yrsUS$84.95k0.11%
$ 22.0k
Thomas Fleming
Member of the Scientific Advisory Boardno datano datano data
Jason Amello
Independent Director6.2yrsUS$83.08k0%
$ 0
Marlene Haffner
Member of the Scientific Advisory Boardno datano datano data
Gerard Berry
Member of the Scientific Advisory Boardno datano datano data

6.2yrs

Average Tenure

66yo

Average Age

Experienced Board: ACER's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/20 16:22
End of Day Share Price 2023/11/17 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acer Therapeutics Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Constantine DavidesD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.